Being A Successful Trader Just Got Easier…
From 10x Trading Champion Chuck Hughes comes the e-book helping thousands to survive the bear market, “Options trading Made Easy”!

Already full of tools and strategies for success, each copy now comes with a daily Trade of the Day, straight from Chuck to you!

Download your copy now!
Briggs Morrison, insider at Arvinas

Briggs Morrison Insider Information

Director of Arvinas
Briggs W. Morrison, M.D., as served as our President, Head of Research and Development since February 2022 and previously served as our Chief Executive Officer since June 2015 and as a member of our board of directors since July 2015. Dr. Morrison currently serves as a managing director of MPM Capital, a healthcare-focused venture capital firm, since June 2015. Prior to joining us, he served as Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca plc, a publicly traded company, from January 2012 to June 2015, leading the company’s global, late-stage development organization and serving as a member of the AstraZeneca senior executive team. He previously held a number of positions at Pfizer Inc., a publicly traded company, from 2007 to January 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer’s human health business, and also served in roles of increasing responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. Dr. Morrison currently serves on the board of Arvinas, Repare Therapeutics and Werewolf Therapeutics, each of which is a publicly traded company, as well as the boards of several private companies. Previously, he served on the board of Codiak Biosciences, Oncorus and NextCure Therapeutics. Dr. Morrison received a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut.

What is Briggs Morrison's net worth?

The estimated net worth of Briggs Morrison is at least $850,578.08 as of April 14th, 2022. Dr. Morrison owns 19,976 shares of Arvinas stock worth more than $850,578 as of July 3rd. This net worth evaluation does not reflect any other investments that Dr. Morrison may own. Learn More about Briggs Morrison's net worth.

How do I contact Briggs Morrison?

The corporate mailing address for Dr. Morrison and other Arvinas executives is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. Arvinas can also be reached via phone at (203) 535-1456 and via email at [email protected] Learn More on Briggs Morrison's contact information.

Has Briggs Morrison been buying or selling shares of Arvinas?

Briggs Morrison has not been actively trading shares of Arvinas during the past quarter. As far as recent transactions, on Sunday, July 3rd, 0 shares of BMO Capital Markets stock. Learn More on Briggs Morrison's trading history.

Who are Arvinas' active insiders?

Arvinas' insider roster includes Sean Cassidy (CFO), John Houston (CEO), Bradley Margus (Director), Briggs Morrison (Director), Ronald Peck (Insider), Liam Ratcliffe (Director), Timothy Shannon (Director), and Ian Taylor (Insider). Learn More on Arvinas' active insiders.

Are insiders buying or selling shares of Arvinas?

In the last year, insiders at the sold shares 29 times. They sold a total of 873,196 shares worth more than $70,467,343.75. The most recent insider tranaction occured on April, 14th when Director Briggs Morrison sold 20,960 shares worth more than $1,392,582.40. Insiders at Arvinas own 2.8 % of the company. Learn More about insider trades at Arvinas.

Information on this page was last updated on 4/14/2022.

Briggs Morrison Insider Trading History at Arvinas

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/14/2022Sell20,960$66.44$1,392,582.4019,976View SEC Filing Icon  
1/14/2022Sell20,960$65.55$1,373,928.00View SEC Filing Icon  
3/24/2020Buy2,500$40.82$102,050.0029,520View SEC Filing Icon  
See Full Table

Briggs Morrison Buying and Selling Activity at Arvinas

This chart shows Briggs Morrison's buying and selling at Arvinas by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Arvinas Company Overview

Arvinas logo
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Read More

Today's Range

Now: $42.58
Low: $40.93
High: $42.71

50 Day Range

MA: $44.39
Low: $36.01
High: $63.33

2 Week Range

Now: $42.58
Low: $34.90
High: $108.46


232,665 shs

Average Volume

421,662 shs

Market Capitalization

$2.26 billion

P/E Ratio


Dividend Yield



Trading With A Small Account?
If you’ve been told it’s not doable, you’ve been lied to! Hi, I’m pro-trader Chuck Hughes and I grew my once tiny investment into an empire!

If you want to do the same–or simply want to feel more secure in your finances–”Options Trading Made Easy” is the guide you need.

Get a copy here!